Disease & disorder

severe pre-eclampsia

MONDO:0001641

Preeclampsia with a systolic blood pressure of 160 mmHg or higher, or a diastolic blood pressure of 110 mmHg or higher on two occasions at least 4 hours apart while on bedrest. It is associated with thrombocytopenia (platelets less than 100,000 per microliter), impaired liver function (twice normal elevation of hepatic transaminases; severe, persistent right upper quadrant or epigastric pain), progressive renal insufficiency (serum creatinine greater than 1.1 mg/dL or doubling of baseline in the absence of other renal disease), pulmonary edema, or new-onset cerebral or visual disturbances.

Clinical trials39
Recruiting2
Drug concepts studied12
Synonyms2

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.

Medications under investigation

Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.

Loading mapped interventions…

MONDO disease family

Loading verified ontology relationships…

Recruiting studies by city

Loading research-site locations…

Trial status

Loading…

Trial phase

Loading…

Study start year

Loading…

Investigated drug interventions

Loading…
Background context

severe pre-eclampsia

Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

39 shown
Role of Postpartum Furosemide in Recovery of Patients With Severe PreeclampsiaNCT07861685 · 2026-10-01
RECRUITING
PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)NCT07263490 · 2024-10-21
RECRUITING
Identification of Genes of Interest for Severe Forms of PreeclampsiaNCT07703826 · 2026-09-01
NOT_YET_RECRUITING
Algorithm-Based Timing of Delivery Using the sFlt-1/PlGF Ratio in Early-Onset Severe Preeclampsia. (MAP 2 Study : Management Based on Angiogenic Markers in Preeclampsia 2 Study )NCT07665112 · 2026-07-01
NOT_YET_RECRUITING
Furosemide vs Placebo in Severe Preeclampsia PostpartumNCT07648251 · 2026-06-15
NOT_YET_RECRUITING
Factors Associated With Blood Pressure Control Failure to Intravenous Labetalol in Severe PreeclampsiaNCT07547046 · 2026-04-01
NOT_YET_RECRUITING
Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic SeizureNCT07220902 · 2026-01-01
NOT_YET_RECRUITING
Excess Base Comparison Between Pregnant Subjects With Severe Preeclampsia vs. Normotensive Pregnant WomenNCT07265336 · 2025-08-15
COMPLETED
Diastolic Dysfunction 2025NCT07190846 · 2025-03-01
COMPLETED
Prevalence of Blood Pressure Complications During Cesarean Section in Pre-eclamptic Patients (HOPE)NCT06588023 · 2024-09-05
UNKNOWN
Protocols for Magnesium Sulfate Maintenance Dose in Overweight and Obese Women Diagnosed With PreeclampsiaNCT06486025 · 2024-07-01
UNKNOWN
Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia.NCT06385600 · 2024-05-20
UNKNOWN
Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual NifedipineNCT06265415 · 2024-03-30
UNKNOWN
Pulmonary Edema Resolution in Severe Preeclampsia and EclampsiaNCT06219109 · 2023-05-08
UNKNOWN
Comparison of Loading Dose Magnesium Sulphate With Prichard Regimen in the Management of Severe Preeclampsia and Eclampsia.NCT06126068 · 2023-01-01
COMPLETED
Serum Magnesium Concentration in Magnesium Sulfate Therapy for Severe PreeclampsiaNCT05283473 · 2022-03-15
COMPLETED
Ultrasonographic Diameter of Optic Nerve Sheath in Fluid Assessment in Severe Preeclamptic PatientsNCT05176652 · 2021-12-06
UNKNOWN
Complement Regulation to Undo Systemic Harm in PreeclampsiaNCT04725812 · 2021-09-13
TERMINATED
The Association Between Different Markers With Development of Maternal and Neonatal Complications in Women With Severe PreeclampsiaNCT07125599 · 2020-05-02
COMPLETED
Nitroglycerin Versus Labetalol in Acute Severe Pre-eclampsiaNCT05310929 · 2019-08-28
COMPLETED
Acute Labetalol Use in PreeclampsiaNCT03872336 · 2019-02-18
TERMINATED
Acute Control of Chronic HypertensionNCT03877692 · 2019-02-18
TERMINATED
Risk Prediction Models for Adverse Maternal and Neonatal Outcomes in PreeclampsiaNCT04058405 · 2018-11-12
COMPLETED
Serum Magnesium Level Administration in Severe Pre-eclampsia Obese PregnancyNCT03661775 · 2018-09-30
COMPLETED
Serum Androgen Levels as a Marker for the Severity of PreeclampsiaNCT03744988 · 2017-10-01
UNKNOWN
Restless Leg Syndrome and Severe PreeclampsiaNCT01538147 · 2017-08-01
COMPLETED
Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsiaNCT03164304 · 2017-05-30
COMPLETED
Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe PreeclampsiaNCT03008616 · 2017-04-12
TERMINATED
Antiphospholipid Antibodies and Early Severe Preeclampsia.NCT01538121 · 2015-06-01
UNKNOWN
Pre-Eclampsia And Growth Restriction: a Longitudinal StudyNCT02379832 · 2015-03-01
COMPLETED
Promising Bimarker Prediction of Outcome of HELLP Syndrome.NCT03246542 · 2015-01-01
COMPLETED
Immature Platelet Fraction as a Promising Biomarker in Prediction Outcome of HELLP SyndromeNCT03232359 · 2015-01-01
COMPLETED
Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following DeliveryNCT02314286 · 2014-12-01
UNKNOWN
First-trimester Prediction of PreeclampsiaNCT02189148 · 2014-11-01
COMPLETED
Evaluation of Metabolic Acid-base Abnormalities in Pre-eclamptic Women Applying the Stewart-Fencl ApproachNCT02164370 · 2013-10-01
COMPLETED
İs There a Relationship Between Severity of Preeclampsia and Maternal Heavy Metal Levels?NCT01906567 · 2013-07-01
UNKNOWN
Dexmedetomidine vs. Remifentanil for Pre-eclampsia During Caesarean DeliveryNCT01766089 · 2013-01-01
COMPLETED
Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe PreeclampsiaNCT01382732 · 2012-01-01
UNKNOWN
Effectiveness Study of Short Course of Magnesium Sulfate for Severe PreeclamsiaNCT01408979 · 2011-08-01
COMPLETED

Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.